Hiroji Iwata
#146,641
Most Influential Person Now
Researcher
Hiroji Iwata's AcademicInfluence.com Rankings
Hiroji Iwatacomputer-science Degrees
Computer Science
#7404
World Rank
#7798
Historical Rank
Machine Learning
#2716
World Rank
#2751
Historical Rank
Artificial Intelligence
#3012
World Rank
#3058
Historical Rank
Database
#4467
World Rank
#4644
Historical Rank
Download Badge
Computer Science
Hiroji Iwata's Degrees
- PhD Computer Science University of Tokyo
- Masters Computer Science University of Tokyo
- Bachelors Computer Science University of Tokyo
Similar Degrees You Can Earn
Why Is Hiroji Iwata Influential?
(Suggest an Edit or Addition)Hiroji Iwata's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. (2005) (4911)
- Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer (2018) (1567)
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. (2016) (1176)
- Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer (2019) (1081)
- Large-scale genotyping identifies 41 new loci associated with breast cancer risk (2013) (1063)
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy (2017) (958)
- Association analysis identifies 65 new breast cancer risk loci (2017) (922)
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. (2019) (777)
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer (2018) (674)
- Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. (2015) (634)
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (616)
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial (2020) (595)
- Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. (2007) (547)
- Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer (2013) (534)
- Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer (2015) (502)
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study (2019) (464)
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial (2020) (416)
- Genome-wide association studies identify four ER negative–specific breast cancer risk loci (2013) (411)
- Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2017) (396)
- Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (2016) (393)
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. (2017) (390)
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study (2019) (368)
- MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer (2019) (266)
- Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study (2020) (263)
- Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. (2013) (225)
- Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer (2010) (193)
- Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. (2019) (187)
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. (2022) (179)
- Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). (2016) (176)
- Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1. (2020) (175)
- Genome-Wide Association Study in East Asians Identifies Novel Susceptibility Loci for Breast Cancer (2012) (160)
- Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. (2012) (154)
- Production of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Human Breast Carcinomas (1996) (142)
- LBA13Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086 (2017) (137)
- Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1 (2014) (132)
- Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. (2020) (130)
- KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. (2020) (129)
- Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial (2016) (128)
- Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. (2017) (127)
- Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer (2010) (127)
- NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese (2002) (127)
- Identification of a Functional Genetic Variant at 16q12.1 for Breast Cancer Risk: Results from the Asia Breast Cancer Consortium (2010) (125)
- Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers (2007) (124)
- Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis (2014) (123)
- One-carbon metabolism-related gene polymorphisms and risk of breast cancer. (2008) (122)
- Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. (2019) (121)
- Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. (2019) (118)
- Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study (2021) (117)
- A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. (2012) (113)
- Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation (2014) (112)
- Clinical significance of the 21‐gene signature (Oncotype DX) in hormone receptor‐positive early stage primary breast cancer in the Japanese population (2010) (111)
- Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. (2013) (109)
- Genome-wide association study identifies breast cancer risk variant at 10q21.2: results from the Asia Breast Cancer Consortium. (2011) (104)
- Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival (2008) (100)
- Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. (2017) (97)
- Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130 (2019) (95)
- Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies (2009) (94)
- Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients (2007) (94)
- Association ofp53 codon arg72pro andp73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of japanese breast cancer (2003) (93)
- Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. (2020) (93)
- Abstract S6-01:PIK3CAstatus in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial: (2016) (92)
- Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls. (2013) (91)
- Replication and functional genomic analyses of the breast cancer susceptibility locus at 6q25.1 generalize its importance in women of chinese, Japanese, and European ancestry. (2011) (90)
- A multicenter validation study of sentinel lymph node biopsy by the Japanese Breast Cancer Society (2000) (89)
- Breast cancer risk and erythrocyte compositions of n‐3 highly unsaturated fatty acids in Japanese (2007) (88)
- A genetic risk predictor for breast cancer using a combination of low-penetrance polymorphisms in a Japanese population (2012) (88)
- Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. (2009) (87)
- Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. (2015) (86)
- Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. (2013) (85)
- Dietary patterns and the risk of breast cancer in Japanese women (2007) (84)
- Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE. (2017) (82)
- Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts. (2018) (82)
- PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients (2017) (77)
- Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial. (2018) (77)
- Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. (2017) (75)
- Association of a polymorphism of the phospholipase D2 gene with the prevalence of colorectal cancer (2003) (75)
- Development of a New Rapid Isolation Device for Circulating Tumor Cells (CTCs) Using 3D Palladium Filter and Its Application for Genetic Analysis (2014) (73)
- DNA methylation analysis at distal and proximal promoter regions of the oestrogen receptor gene in breast cancers (1999) (71)
- Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study (2018) (69)
- Soybean products and reduction of breast cancer risk: a case–control study in Japan (2005) (67)
- Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). (2010) (67)
- IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). (2019) (67)
- Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer (2017) (66)
- Insulin, insulin-like growth factor-I and breast cancer risk in Japanese women. (2003) (63)
- Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study. (2018) (63)
- Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma (2016) (63)
- A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients (2019) (63)
- Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium (2014) (62)
- PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer (2021) (62)
- Transforming growth factor B1 T29C polymorphism and breast cancer risk in Japanese women (2003) (62)
- Adjuvant and neoadjuvant therapy for breast cancer. (2020) (61)
- Microsatellite instability in sporadic human breast cancers (1996) (61)
- Clinical significance of the expression of estrogen receptors α and β for endocrine therapy of breast cancer (2003) (60)
- Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2 (2013) (60)
- Gelatinolytic activity of matrix metalloproteinase-2 and -9 in oesophageal carcinoma; a study using in situ zymography. (2000) (60)
- Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. (2022) (59)
- Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab +nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer (2019) (57)
- Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression (2014) (57)
- A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017. (2012) (56)
- Current approach and future perspective for ductal carcinoma in situ of the breast (2017) (55)
- FGFR2 intronic polymorphisms interact with reproductive risk factors of breast cancer: Results of a case control study in Japan (2009) (54)
- Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer (2013) (52)
- Possible association of β2- and β3-adrenergic receptor gene polymorphisms with susceptibility to breast cancer (2001) (52)
- Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. (2011) (52)
- Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer. (2020) (51)
- Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial (2019) (51)
- Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition (2011) (51)
- Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. (2015) (51)
- Association between vitamin D and calcium intake and breast cancer risk according to menopausal status and receptor status in Japan (2010) (50)
- Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2 (2015) (50)
- Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. (2018) (49)
- Abstract S1-07: A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04) (2016) (49)
- A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer (2013) (47)
- Effect of soybean on breast cancer according to receptor status: A case–control study in Japan (2008) (46)
- Analysis of Oncogenes and Tumor Suppressor Genes in Human Breast Cancer (1993) (46)
- Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. (2003) (45)
- Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)]. (2011) (44)
- The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status (2021) (44)
- Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. (2001) (43)
- Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study (2010) (42)
- Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer. (2016) (40)
- Genome-wide association study in East Asians identifies two novel breast cancer susceptibility loci. (2016) (39)
- No Association of the 5′Promoter Region Polymorphism of CYP17 with Breast Cancer Risk in Japan (2000) (39)
- Significant reduction in breast cancer risk for Japanese women with interleukin 1B -31 CT/TT relative to CC genotype. (2002) (38)
- Clinical significance of bcl-2 gene expression in human breast cancer tissues (2004) (38)
- First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study (2011) (38)
- The international collaboration of active surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA). (2019) (37)
- Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer (2020) (37)
- Alcohol Consumption and Survival after a Breast Cancer Diagnosis: A Literature-Based Meta-analysis and Collaborative Analysis of Data for 29,239 Cases (2014) (36)
- Four Cases of Chylous Fistula after Breast Cancer Resection (2004) (35)
- Reproductive and hormonal risk factors for luminal, HER2-overexpressing, and triple-negative breast cancer in Japanese women. (2012) (34)
- Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients (2018) (34)
- Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients. (2020) (34)
- Interaction of the Effects of Alcohol Drinking and Polymorphisms in Alcohol-Metabolizing Enzymes on the Risk of Female Breast Cancer in Japan (2009) (34)
- Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3. (2021) (33)
- Estrogen Receptor, c‐erbB‐2 and nm23/NDP Kinase Expression in the Intraductal and Invasive Components of Human Breast Cancers (1992) (32)
- The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition (2020) (32)
- Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients (2018) (32)
- Brain metastases in breast cancer. (2014) (32)
- PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. (2015) (31)
- Recent Improvement in the Long-term Survival of Breast Cancer Patients by Age and Stage in Japan (2018) (31)
- Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. (2020) (30)
- Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis (2014) (30)
- LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer (2020) (30)
- Alcohol and dietary folate intake and the risk of breast cancer: a case–control study in Japan (2013) (30)
- Impact of prophylactic pyridoxine on occurrence of hand–foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer (2010) (30)
- Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy (2016) (29)
- Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130) (2019) (29)
- PIK3CA Status in Circulating Tumor DNA Predicts Efficacy of Buparlisib Plus Fulvestrant in Postmenopausal Women With Endocrine-resistant HR+/HER2- Advanced Breast Cancer: First Results From the Randomized, Phase III BELLE-2 Trial (2015) (29)
- The CYP19 gene codon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese. (2004) (28)
- Abstract PD6-10: KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC) (2018) (28)
- Palbociclib in combination with letrozole as first‐line treatment for advanced breast cancer: A Japanese phase II study (2018) (27)
- Microsatellite instability in in situ and invasive sporadic breast cancers of Japanese women. (1996) (27)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. (2020) (27)
- The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130. (2021) (26)
- TNM classification of malignant tumors (Breast Cancer Study Group) (2018) (26)
- Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE. (2020) (26)
- Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET). (2015) (26)
- A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment (2009) (26)
- Clinical development of CDK4/6 inhibitor for breast cancer (2018) (26)
- The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis, 2018 Edition (2019) (25)
- Psychometric properties of the Japanese version of the Concerns About Recurrence Scale (CARS-J). (2014) (25)
- Comparison of an AC‐taxane versus AC‐free regimen and paclitaxel versus docetaxel in patients with lymph node‐positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study (2017) (25)
- Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors. (2017) (25)
- Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG (2015) (25)
- Identification of cancer antigens in breast cancer by the SEREX expression cloning method (1999) (25)
- Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples (2019) (25)
- Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants (2020) (25)
- Future treatment strategies for metastatic breast cancer: curable or incurable? (2012) (24)
- Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer (2010) (24)
- Abstract P6-17-06: Characterization, monitoring and management of interstitial lung disease in patients with metastatic breast cancer: Analysis of data available from multiple studies of DS-8201a, a HER2-targeted antibody drug conjugate with a topoisomerase I inhibitor payload (2019) (23)
- FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium (2014) (22)
- Pathway Analyses Identify TGFBR2 as Potential Breast Cancer Susceptibility Gene: Results from a Consortium Study among Asians (2012) (22)
- Occult breast cancer may originate from ectopic breast tissue present in axillary lymph nodes (2018) (22)
- Analysis of Ki‐67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer (2013) (22)
- Advances in treatment and care in metastatic breast cancer (MBC): are there MBC patients who are curable? (2018) (22)
- Contribution of problem-solving skills to fear of recurrence in breast cancer survivors (2014) (21)
- The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition (2019) (21)
- Genetic and Epigenetic Alterations of the Estrogen Receptor Gene and Hormone Independence in Human Breast Cancer (1998) (20)
- A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients (2013) (20)
- Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy (2015) (20)
- Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG (2014) (19)
- Abstract P6-17-02: Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study (2019) (19)
- Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma (2005) (19)
- 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy (2014) (19)
- Smartphone problem-solving and behavioural activation therapy to reduce fear of recurrence among patients with breast cancer (SMartphone Intervention to LEssen fear of cancer recurrence: SMILE project): protocol for a randomised controlled trial (2018) (19)
- A single-arm, phase 2 study of steroid-containing mouthwash for the prevention of everolimus-associated stomatitis in multiple tumor types (2019) (19)
- Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer (2020) (19)
- Health-related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer (2014) (19)
- Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results from a phase I/II trial. (2019) (19)
- High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers (2012) (18)
- Abstract PD1-07: Exploratory analytical harmonization of PD-L1 immunohistochemistry assays in advanced triple-negative breast cancer: A retrospective substudy of IMpassion130 (2020) (18)
- Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study (2017) (18)
- Localization of gelatinolytic activity can be detected in Breast Cancer tissues by filmin situ zymography (2001) (18)
- Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer. (2010) (18)
- Sentinel lymph node biopsy is not necessary in patients diagnosed with ductal carcinoma in situ of the breast by stereotactic vacuum-assisted biopsy (2016) (18)
- Evaluation of trastuzumab without chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients: Randomized controlled trial (RESPECT). (2018) (17)
- Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm (2018) (17)
- Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer From SOLAR-1 (2021) (17)
- Clinical significance of estrogen receptor β in breast cancer (1999) (17)
- Combination of subareolar blue dye and peritumoral RI for sentinel lymph node biopsy (2002) (17)
- Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer (2013) (17)
- Phase III Randomized Trial of Sunitinib (SU) vs. Capecitabine (C) in Patients (Pts) with Previously Treated HER2-Negative Advanced Breast Cancer (ABC). (2009) (17)
- Impact of intraoperative specimen mammography on margins in breast-conserving surgery. (2016) (17)
- Absence of the caveolin-1 P132L mutation in cancers of the breast and other organs. (2010) (17)
- SOLAR-1: A phase III study of alpelisib + fulvestrant in men and postmenopausal women with HR+/HER2– advanced breast cancer (BC) progressing on or after prior aromatase inhibitor therapy. (2016) (17)
- Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). (2022) (16)
- Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer. (2020) (16)
- Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study (2022) (16)
- Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer. (2018) (16)
- Abstract GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03 (2022) (16)
- A49T, V89L and TA repeat polymorphisms of steroid 5α-reductase type II and breast cancer risk in Japanese women (2002) (16)
- Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication (2019) (16)
- Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer (2021) (15)
- Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer. (2015) (15)
- Abstract P4-22-06: Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3 (2017) (15)
- Randomized phase II study of nab‐paclitaxel as first‐line chemotherapy in patients with HER2‐negative metastatic breast cancer (2017) (14)
- Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial (2022) (14)
- LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC) (2020) (14)
- Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer (2017) (14)
- Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer. (2012) (14)
- Circulating tumor cells detection in tumor draining vein of breast cancer patients (2019) (14)
- 92O Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd) (2021) (14)
- Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. (2019) (14)
- Ex vivo culture of circulating tumor cells using magnetic force‐based coculture on a fibroblast feeder layer (2016) (14)
- Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis (2020) (14)
- Differential impact of body mass index and its change on the risk of breast cancer by molecular subtype: A case-control study in Japanese women (2012) (14)
- Comparison of sentinel lymph node biopsy between invasive lobular carcinoma and invasive ductal carcinoma (2018) (14)
- Patient-reported outcomes and objective assessments with arm measurement and bioimpedance analysis for lymphedema among breast cancer survivors (2019) (14)
- Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus (2016) (14)
- Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study. (2018) (14)
- 296P Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial (2020) (13)
- Simultaneous quantitative analyses of c-erbB-2 protein, epidermal growth factor receptor, cathepsin D, and hormone receptors in breast cancer. (1997) (13)
- A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance (2012) (13)
- PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial (2019) (13)
- Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial (2018) (13)
- Final Results of a Safety and Efficacy Trial of Preoperative Sequential Chemoradiation Therapy for the Nonsurgical Treatment of Early Breast Cancer: Japan Clinical Oncology Group Study JCOG0306 (2013) (13)
- Perspective of trastuzumab treatment (2007) (13)
- Intensive vs. Standard Post-Operative Surveillance in High-Risk Breast Cancer Patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204. (2015) (13)
- Dose-Finding Phase I and Pharmacokinetic Study of Capecitabine (Xeloda) in Combination with Epirubicin and Cyclophosphamide (CEX) in Patients with Inoperable or Metastatic Breast Cancer (2008) (13)
- Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086 (2019) (13)
- The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2018 edition (2019) (12)
- Efficient capturing of circulating tumor cells using a magnetic capture column and a size-selective filter (2015) (12)
- Title Identification of a functional genetic variant at 16 q 12 . 1 for breastcancer risk : results from the Asia Breast Cancer Consortium (2010) (12)
- A randomized controlled trial comparing primary tumor resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (JCOG1017 PRIM-BC). (2017) (12)
- Risks and benefits of bevacizumab combined with chemotherapy for advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials (2020) (12)
- Abstract GS1-03: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01) (2020) (12)
- Feasibility of intraoperative radiation therapy for early breast cancer in Japan: a single-center pilot study and literature review (2014) (12)
- Low expression of the snail gene is a good prognostic factor in node-negative invasive ductal carcinomas. (2006) (12)
- Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment. (2013) (12)
- Acute phase dynamics of circulating tumor cells after paclitaxel and doxorubicin chemotherapy in breast cancer mouse models (2017) (12)
- A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE). (2011) (12)
- Clinical and pathologic factors predicting axillary lymph node involvement in breast cancer (2000) (12)
- GANP protein encoded on human chromosome 21/mouse chromosome 10 is associated with resistance to mammary tumor development (2016) (11)
- [Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of BOLERO -2]. (2015) (11)
- Evaluation of the Association of Polymorphisms With Palbociclib‐Induced Neutropenia: Pharmacogenetic Analysis of PALOMA‐2/‐3 (2021) (11)
- Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer (2004) (11)
- Abstract S5-02: Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: 3-year analysis from a phase 3 randomized, placebo-controlled, double-blind trial (ExteNET) (2016) (11)
- Impact of intrinsic subtype on predicting axillary lymph node metastasis in breast cancer (2014) (11)
- Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancer. (2012) (11)
- Histological classification of breast tumors in the General Rules for Clinical and Pathological Recording of Breast Cancer (18th edition) (2020) (11)
- Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer (2021) (11)
- Identification and characterization of novel associations in the CASP 8 / ALS 2 CR 12 region on chromosome 2 with breast cancer risk (2014) (11)
- [The expression of MMPs and TIMPs in human breast cancer tissues and importance of their balance in cancer invasion and metastasis]. (1995) (11)
- Phase II study of gemcitabine monotherapy as a salvage treatment for Japanese metastatic breast cancer patients after anthracycline and taxane treatment. (2009) (11)
- Reproductive and hormonal risk factors for luminal, HER2-overexpressing, and triple-negative breast cancer in Japanese women. (2012) (11)
- LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) (2020) (11)
- Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan (2008) (11)
- IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). (2018) (10)
- Prognostic Factors for Overall Survival in Patients with Hormone Receptor‐Positive Advanced Breast Cancer: Analyses From PALOMA‐3 (2021) (10)
- Detection of DNA fragmentation in human breast cancer tissue by an antibody specific to single-stranded DNA (1998) (10)
- Abstract P4-10-04: Clinical outcomes of alpelisib in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer by next-generation sequencing-detected PIK3CA alteration status and phosphatase and tensin homolog loss: Biomarker analysis from the SOLAR-1 study (2020) (10)
- Expression of estrogen receptor α exon 5 and 7 deletion variant in human breast cancers (2000) (10)
- Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan (2021) (10)
- Abstract PD3-07: Safety and efficacy results from a phase 1 study of DS-8201a in patients with HER2 expressing breast cancers (2018) (10)
- Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401) (2014) (10)
- Cytoplasmic expression of the JM403 antigen GlcA-GlcNH3+ on heparan sulfate glycosaminoglycan in mammary carcinomas—a novel proliferative biomarker for breast cancers with high malignancy (2010) (9)
- Equivalent cross‐relaxation rate imaging for sentinel lymph node biopsy in breast carcinoma (2005) (9)
- Abstract PD1-03: Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results of a phase 1/2 trial (2019) (9)
- Incidence of contralateral breast cancer in Japanese patients with unilateral minimum-risk primary breast cancer, and the benefits of endocrine therapy and radiotherapy (2014) (9)
- The clinical value of microsatellite instability and a loss in heterozygosity in sporadic breast cancers (1997) (9)
- Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial (2014) (9)
- Equivalent cross‐relaxation rate imaging of axillary lymph nodes in breast cancer (2008) (9)
- P1-12-19: Phase I Study of Single Agent Trastuzumab Emtansine in Japanese Patients with Human Epidermal Growth Factor Receptor2 (HER2)-Positive Metastatic Breast Cancer (JO22591). (2011) (9)
- Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy – results from Paloma-3. (2016) (9)
- Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial (2021) (9)
- Bone Scan Index predicts skeletal-related events in patients with metastatic breast cancer (2016) (9)
- Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept (2011) (9)
- Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03 (2018) (9)
- The Japanese Breast Cancer Society Clinical Practice Guidelines, 2018 edition: the tool for shared decision making between doctor and patient (2019) (9)
- Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Analyses from PALOMA-3. (2018) (9)
- Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer. (2019) (8)
- Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer (2021) (8)
- Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2. (2013) (8)
- A phase 3 study of alpelisib (ALP) plus fulvestrant (FUL) in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) ABC progressing on or after aromatase inhibitor (AI) therapy: SOLAR-1. (2017) (8)
- Amyloid tumor of the breast (2019) (8)
- AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer (2022) (8)
- Neutropenia management with palbociclib in Japanese patients with advanced breast cancer (2019) (8)
- A randomized phase II study evaluating pyridoxine for the prevention of hand–foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer (2018) (8)
- Abstract OT2-08-02: Capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer: A phase III trial (CAPItello-290) (2020) (8)
- Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer (2015) (8)
- Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study (2013) (8)
- Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets). (2012) (7)
- Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer (2021) (7)
- [Results of a drug use investigation of nanoparticle albumin-bound Paclitaxel for breast cancer]. (2015) (7)
- Polymorphism of dihydropyrimidine dehydrogenase (DPYD) Cys29Arg and risk of six malignancies in Japanese. (2005) (7)
- Phase III trial comparing 4-cycle doxorubicin plus cyclophosphamide followed by 4-cycle taxan with 8-cycle taxan as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02 trial. (2016) (7)
- A functional single nucleotide polymorphism in ABCC11, rs17822931, is associated with the risk of breast cancer in Japanese. (2019) (7)
- Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials (2021) (7)
- Omitting surgery for early breast cancer showing clinical complete response to primary systemic therapy. (2020) (7)
- Impact of BMI for clinical outcomes in Japanese breast cancer patients. (2020) (7)
- Abstract PS12-10: Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR+, HER2- metastatic breast cancer: WJOG11418B NEWFLAME trial (2021) (7)
- Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. (2021) (7)
- Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial (2017) (7)
- Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086 (2021) (7)
- Randomized phase II study of three doses of oral TAS‐108 in postmenopausal patients with metastatic breast cancer (2012) (7)
- Role of matrix metalloproteinase‐9 in in vitro invasion of esophageal carcinoma cells (2002) (7)
- A case of invasive micropapillary carcinoma of the breast (2007) (7)
- SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease. (2021) (7)
- A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane (2013) (7)
- A case of giant cell tumor of the breast, clinically suspected as malignant breast tumor (2019) (7)
- Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer. (2014) (7)
- Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study (2021) (6)
- Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03. (2022) (6)
- Significance of primary lesion resection in Stage IV breast cancer (2017) (6)
- First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis (2020) (6)
- A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC). (2011) (6)
- Effects of neoadjuvant chemotherapy on operative adverse events and chemotherapy and radiotherapy in patients undergoing immediate breast reconstruction (2020) (6)
- 149ONeratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial (2017) (6)
- A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S−1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG‐M01 study) (2017) (6)
- Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study. (2016) (6)
- Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation (2018) (6)
- Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01 (2020) (6)
- Prediction of pathological margin status using preoperative contrast‐enhanced MRI in patients with early breast cancer who underwent skin‐sparing mastectomy (2019) (6)
- Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer (2004) (6)
- Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy (2021) (6)
- Abstract CT167: Pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies (2021) (6)
- Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03) (2022) (5)
- Pharmacogenomic–pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer (2019) (5)
- Detection of parasternal metastatic lymph nodes by sentinel lymph node methods in a patient with recurrence in the conserved breast (2014) (5)
- A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1. (2018) (5)
- 409PUpdated results of phase 1 study of DS-8201a in patients with HER2 expressing non-breast, non-gastric malignancies (2017) (5)
- Abstract P2-13-01: Efficacy of neratinib in hormone receptor-positive patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer: Subgroup analyses from the phase III ExteNET trial (2019) (5)
- Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: Subgroup analysis of two phase 1 studies. (2021) (5)
- Low frequency loss of heterozygosity in theBRCA1 region in Japanese sporadic breast cancer (1996) (5)
- Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. (2019) (5)
- Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nabpaclitaxel (nP) in metastatic triple-negative breast cancer (mTNBC). (2019) (5)
- Clinical significance of cathepsin D assay in breast cancer tissues (1995) (5)
- Multicenter Phase II Study of Intraoperative Radiotherapy of Early Breast Cancer: Ipsilateral Tumor Recurrence (2019) (5)
- Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404 (2014) (5)
- Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients (2015) (5)
- Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial. (2013) (5)
- Phase II Clinical Study of Protection of Nail Change and Skin Toxicity by Using a Frozen Glove in Japanese Patients with Early Breast Cancer Treated by Docetaxel and Cyclophosphamide (TC) [TBCRG-03 Study]. (2009) (5)
- Abstract P5-18-16: A Multicenter Phase 2 Study (JO22997) Evaluating the Efficacy and Safety of Trastuzumab Emtansine in Japanese Patients With Heavily Pretreated HER2-Positive Metastatic Breast Cancer (2012) (5)
- Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study (2017) (5)
- Assessing residual cancer cells using MRI and US after preoperative chemotherapy in primary breast cancer to omit surgery (2018) (5)
- A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study. (2018) (5)
- Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary report (2020) (5)
- A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290). (2020) (5)
- Application of a continual reassessment method to a phase I clinical trial of capecitabine in combination with cyclophosphamide and epirubicin (CEX) for inoperable or recurrent breast cancer. (2004) (4)
- [Gemcitabine-induced tumor lysis syndrome caused by recurrent breast cancer in a patient without hemodialysis]. (2013) (4)
- The effect of pathological response of multicenter phase II trial of fluorouracil, epirubicin, cyclophosphamide (FEC 100) followed by docetaxel (DOC 75) in primary operable breast cancer (JBCRG01: Japan Breast Cancer Research Group) (2006) (4)
- Abstract GS1-09: Addition of S-1 to endocrine therapy in the post-operative adjuvant treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative primary breast cancer: A multicenter, open-label, phase 3 randomized trial (POTENT trial) (2020) (4)
- Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management (2022) (4)
- 96OMONARCH 2: Abemaciclib in combination with fulvestrant in Asian women with HR+, HER2- advanced breast cancer who progressed on endocrine therapy (2017) (4)
- Clinical usefulness of oral combination chemotherapy of 5′;-deoxy-5-fluorouridine (5′;-DFUR) and cyclophosphamide for metastatic Breast Cancer (2006) (4)
- Abstract OT3-2-10: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) ± goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) whose disease progressed after prior endocrine therapy (2013) (4)
- Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study (2020) (4)
- Association of Parity and Infant Feeding Method with Breast Density on Mammography. (2020) (4)
- Alpelisib (ALP) + fulvestrant (FUL) for patients with hormone receptor–positive (HR+), HER2− advanced breast cancer (ABC): Management and time course of key adverse events of special interest (AESIs) in SOLAR-1 (2019) (4)
- Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3 (2020) (4)
- Increased chemosensitivity via BRCA2-independent DNA damage in DSS1- and PCID2-depleted breast carcinomas (2021) (4)
- Abstract OT2-3-09: Phase III randomized study of the oral pan-PI3K inhibitor BKM120 with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer resistant to aromatase inhibitor – BELLE-2 (2012) (4)
- Practical Application of the Continual Reassessment Method to a Phase I Dose-Finding Trial in Advanced Breast Cancer (2007) (4)
- The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial (2019) (4)
- Comorbid insomnia among breast cancer survivors and its prediction using machine learning: a nationwide study in Japan (2021) (4)
- A case of radiation-associated angiosarcoma after breast cancer (2018) (4)
- Abstract P6-17-10: Dose justification for DS-8201a, a HER2-targeted antibody-drug conjugate, for HER2-positive breast cancer: Observed clinical data and exposure-response analyses (2019) (3)
- Brief screening of patients with distressing fear of recurrence in breast cancer survivors (2015) (3)
- Abstract P1-14-02: Preoperative docetaxel (T) with or without capecitabine (X) following epirubicin, 5-fluorouracil and cyclophosphamide (FEC) in patients with operable breast cancer (OOTR N003): Results of comparative study and predictive marker analysis (2012) (3)
- Abstract PD2-06: Clinical outcomes of alpelisib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer withPIK3CAalterations detected in plasma ctDNA by next-generation sequencing: Biomarker analysis from the SOLAR-1 study (2021) (3)
- [Molecular analysis of the estrogen receptor (ER) gene in association with ER negativity in breast cancer]. (1996) (3)
- A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1) (2016) (3)
- A case of metastatic breast cancer achieving complete response by combination therapy with 5’-deoxy-5-fluorouridine and cyclophosphamide (2000) (3)
- Current Status of Advance Care Planning and End‐of‐life Communication for Patients with Advanced and Metastatic Breast Cancer (2020) (3)
- 177PEffects of neratinib (N) on health-related quality of life (HRQoL) in early-stage HER2+ breast cancer (BC): longitudinal analyses from the phase III ExteNET trial (2017) (3)
- [Clinical efficacy and safety assessment of eribulin monotherapy in patients with metastatic breast cancer - a single- institute experience]. (2013) (3)
- Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer : a postmarketing observational study (2017) (3)
- Abstract P1-13-03: Effects of neratinib after trastuzumab-based adjuvant therapy in hormone receptor-positive HER2+ early-stage breast cancer: Exploratory analyses from the phase III ExteNET trial (2018) (3)
- Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer. (2010) (3)
- Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial. (2019) (3)
- Consecutively occurring multiple fibroadenomas of the breast distinguished from phyllodes tumors by clonality analysis of stromal tissue (1999) (3)
- Abstract CT040: MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2- advanced breast cancer - Results from the preplanned final PFS analysis (2018) (3)
- Outcomes of Japanese breast cancer patients treated with pre‐operative and post‐operative anastrozole or tamoxifen (2012) (3)
- Abstract OT2-04-07: Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer (WJOG11418B, NEWFLAME trial) (2020) (3)
- Subgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries (2019) (3)
- Abstract PD3-03: Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial (2021) (3)
- 250PA global phase III clinical study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients (2017) (3)
- Abstract P1-13-11: Neratinib in the extended adjuvant treatment of patients from Asia with early-stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial (2018) (3)
- Oncology care providers’ awareness and practice related to physical activity promotion for breast cancer survivors and barriers and facilitators to such promotion: a nationwide cross-sectional web-based survey (2021) (2)
- A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: (JCOG1607 HERB TEA study). (2019) (2)
- Expression of estrogen receptor alpha exon 5 and 7 deletion variant in human breast cancers. (2000) (2)
- [Assessment of the clinical efficacy and safety of fulvestrant in heavily pretreated patients with hormone-receptor positive metastatic breast cancer-a single-institution experience]. (2013) (2)
- Impact of abemaciclib on the time to subsequent chemotherapy and the time to second disease progression across the MONARCH 2 and 3 studies. (2018) (2)
- Abstract P1-12-01: Evaluation on efficacy and safety of capecitabine plus docetaxel versus docetaxel monotherapy in metastatic breast cancer patients pretreated with anthracycline: Results from a randomized phase III study (JO21095) (2012) (2)
- Abstract PD3-11: A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study (2021) (2)
- Efficacy of first-line bevacizumab (Bev) combined with weekly paclitaxel (wPac) for HER2-negative metastatic breast cancer (MBC): Results of a Japanese phase II study (n=120). (2011) (2)
- The transition of breast cancer treatment and Japan Clinical Oncology Group research over two decades. (2012) (2)
- Dose-dense adjuvant chemotherapy: a systematic review and meta-analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2018 edition (2020) (2)
- 43O Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia (2020) (2)
- PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 (2022) (2)
- Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial (2020) (2)
- Mechanisms and anatomical risk factors of pneumothorax after Bevacizumab use: A case report (2020) (2)
- Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study (2022) (2)
- Feasibility study of contralateral risk-reducing mastectomy with breast reconstruction for breast cancer patients with BRCA mutations in Japan (2018) (2)
- Abstract OT2-11-06: SERENA-4: A Phase III comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive/HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease (2022) (2)
- IMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC). (2019) (2)
- Abstract OT2-6-02: Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): A global, placebo-controlled, randomized, double-blind, phase 3 clinical trial (2013) (2)
- Impact of Tumor Progression on Survival During Neoadjuvant Chemotherapy in Breast Cancer: A Cohort Study (2021) (2)
- Presence of small residual malignant lesions in pathologic complete response after neo‐adjuvant chemotherapy in patients with breast cancer (2019) (2)
- Nuclear grade and comedo necrosis of ductal carcinoma in situ as histopathological eligible criteria for the Japan Clinical Oncology Group 1505 trial: an interobserver agreement study. (2021) (2)
- Dose justification for [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-positive breast cancer (2019) (2)
- Abstract PD1-09: Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC) (2021) (2)
- Immediate one-stage implant-based breast reconstruction without the use of acellular dermal matrix in Japanese breast cancer patients (2020) (2)
- Abstract P1-12-03: The STAGE Study: A Phase III Comparison of Anastrozole Plus Goserelin with Tamoxifen Plus Goserelin as Pre-Operative Treatments in Premenopausal Breast Cancer Patients (2010) (2)
- Association of drug-related polymorphisms with palbociclib-related neutropenia: Pharmacogenetic analysis of PALOMA-2/-3 (P2/3). (2019) (2)
- Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study. (2009) (2)
- P203 Dual HER2 blockage with lapatinib and trastuzumab for Japanese patients with HER2+ breast cancer (2015) (2)
- The overall survival of breast cancer patients without adjuvant therapy (2019) (2)
- Rainbow of KIBOU (ROK) study: a Breast Cancer Survivor Cohort in Japan (2017) (2)
- Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: First safety analysis of CREATE-X (JBCRG-04) (2013) (2)
- Denosumab Versus Placebo as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Disease Recurrence (D-CARE): An in Progress, Phase 3 Clinical Trial (2012) (2)
- Palbociclib as an early-line treatment for Japanese patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: a review of clinical trial and real-world data (2021) (2)
- Abstract P4-13-03: Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy (2016) (2)
- Phase III two by two factorial comparison of doxorubicin and cyclophosphamide followed by a taxanvs.a taxan alone, and paclitaxelvs.docetaxel in operable node positive breast cancer – results of the first interim analysis of NSASBC02 trial. (2009) (2)
- Oral uracil-tegafur (UFT) compared to classical cyclophosphamide/methotrexate/5-fluorouracil (CMF) as postoperative chemotherapy in patients with node-negative, high-risk breast cancer (BC): Results of the national surgical adjuvant study for breast cancer (2007) (2)
- Practice management for elderly patients with breast cancer; Findings from a survey by the Japan Breast Cancer Study Group (2018) (2)
- [A Phase I Combination Dose-Escalation Study of Eribulin Mesylate and Gemcitabine in Japanese Patients with Metastatic Breast Cancer]. (2018) (2)
- Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial. (2022) (2)
- Patient-reported outcomes (PROs) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from SOLAR-1. (2019) (2)
- Genome- and transcriptome-wide association studies of 386,000 Asian and European-ancestry women provide new insights into breast cancer genetics. (2022) (2)
- PD07-02: Docetaxel Is Superior to Paclitaxel Given Every Three Weeks in Post Operative Patients with Node-Positive Breast Cancer: Results of the Final Analyses of the NSAS-BC (National Surgical Adjuvant Study of Breast Cancer) 02 Trial from Japan. (2011) (2)
- The investigation study using a questionnaire about the employment of Japanese breast cancer patients (2018) (2)
- Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS) (2022) (2)
- Abstract OT2-3-03: Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase 3 clinical trial (2012) (2)
- Phase II randomized trial of toremifene 120 mg compared with exemestane 25 mg after prior nonsteroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive breast cancer. (2012) (2)
- Duration of extended adjuvant therapy with neratinib in early-stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial. (2018) (2)
- Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study) (2021) (2)
- Adjuvant Olaparib in BRCA-Mutated Breast Cancer. (2021) (2)
- Study protocol for a nationwide questionnaire survey of physical activity among breast cancer survivors in Japan (2020) (2)
- Incidence of contralateral and ipsilateral breast cancers and prognosis in BRCA1/2 pathogenic variant carriers based on the Japanese HBOC Consortium registration (2020) (1)
- N-SAS BC06: A phase III study of adjuvant endocrine therapy with or without chemotherapy for postmenopausal breast cancer patients who responded to neoadjuvant letrozole (LET): The New Primary Endocrine-Therapy Origination Study (NEOS). (2013) (1)
- Clinical Utility of Precision Medicine in Early Breast Cancer: What Is the Optimal Framework to Develop Precision Medicine? (2022) (1)
- Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study (2022) (1)
- 459 Monthly versus three-monthly goserelin treatment in premenopausal patients with oestrogen receptor-positive early breast cancer (2010) (1)
- 235TiPA Phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours, hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer (BC; +/-endocrine therapy), or non-small-cell lung cancer (NSCLC) (2017) (1)
- A randomized phase II study evaluating the use of prydoxine to prevent hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer. (2014) (1)
- 253PAbemaciclib plus fulvestrant in patients (pts) with HR+/HER2- endocrine therapy naïve (EN) advanced breast cancer - an exploratory analysis of MONARCH 2 (2017) (1)
- Abstract OT3-13-01: Estimation of willingness-to-pay for breast cancer treatments through contingent valuation method in Japanese breast cancer patients (JCOG1709A) (2020) (1)
- Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants (2020) (1)
- Abstract P4-11-02: Subjective and objective assessment of efficacy of frozen gloves and socks to prevent nab-paclitaxel-induced peripheral neuropathy in patients with breast cancer (2019) (1)
- Flow Cytometric Assay of c-erbB-2 Protein in Fine Needle Aspirates of Fresh and Frozen Human Breast Cancer Tissues (1996) (1)
- Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study (2018) (1)
- A systematic literature review of prognostic factors in patients with HR+/HER2− advanced breast cancer in Japan (2021) (1)
- Abstract 06: A genetic risk predictor for breast cancer using a combination of low-penetrance polymorphisms in a Japanese population. (2012) (1)
- A multicenter, randomized phase II study of neoadjuvant chemotherapy including trastuzumab with cyclophosphamide with docetaxel in patients with operable HER2-positive breast cancer (JBCRG-10 study). (2010) (1)
- Smartphone Psychotherapy Reduces Fear of Cancer Recurrence Among Breast Cancer Survivors: A Fully Decentralized Randomized Controlled Clinical Trial (J-SUPPORT 1703 Study) (2022) (1)
- MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer (2019) (1)
- A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer (JCOG1607 HERB TEA study). (2018) (1)
- Neo(adjuvant) trastuzumab treatment: current perspectives (2009) (1)
- Abstract P4-13-01: PALOMA3: Phase 3 trial of fulvestrant with or without palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy—confirmed efficacy and safety (2016) (1)
- Abstract PD5-12: Buparlisib (BUP) or placebo (PBO) plus fulvestrant (FUL) in postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Overall survival (OS) results from BELLE-2, a randomized, phase III (2018) (1)
- Abstract P5-21-13: Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial (2018) (1)
- Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER 2-positive metastatic breast cancer (2014) (1)
- [Prognostic significance of loss of heterozygosity in breast cancer]. (1998) (1)
- Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase III clinical trial. (2012) (1)
- Safety of trastuzumab in HER2-positive primary breast cancer in Japan: Initial safety report for the large-scale cohort study (JBCRG C-01). (2013) (1)
- 0174 A phase III study of adjuvant endocrine therapy with or without chemotherapy for postmenopausal breast cancer patients who responded to neoadjuvant letrozole: Study design of the new primary endocrine-therapy origination study [NEOS (N-SAS BC06)] (2009) (1)
- AMEERA-5: A randomized, double-blind phase III study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer. (2021) (1)
- Abstract OT3-06-02: A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, including hormone receptor-positive, HER2-negative breast cancer (plus endocrine therapy) (2018) (1)
- Predictors of efficacy in patients (pts) with hormone receptor–positive/ human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC): Subgroup analyses of PALOMA-3 (2020) (1)
- Abstract P2-13-07: Long-term follow-up data of the side effect profile of anastrozole compared with tamoxifen in Japanese women: findings from N-SAS BC03 trial. (2012) (1)
- Abstract P1-13-05: Timing of initiation of neratinib after completion of trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Exploratory analyses from the phase III ExteNET trial (2018) (1)
- Time to Chemotherapy for Patients With Estrogen Receptor-Positive Breast Cancer and Cyclin-Dependent Kinase 4 and 6 Inhibitor Use (2022) (1)
- Prospective observational study estimating willingness-to-pay for breast cancer treatments through contingent valuation method in Japanese breast cancer patients (JCOG1709A) (2021) (1)
- Neoadjuvant anastrozole or tamoxifen for premenopausal breast cancer: Ki67 expression data from the STAGE study. (2011) (1)
- Real-world treatment patterns of palbociclib and blood count monitoring in patients with advanced breast cancer in Japan. (2022) (1)
- Utility of regional nodal irradiation in Japanese patients with breast cancer with 1-3 positive nodes after breast-conserving surgery and axillary lymph-node dissection. (2020) (1)
- OT1-01-03: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Comparing Denosumab with Placebo as Adjuvant Treatment for Women with Early-Stage Breast Cancer Who Are at High Risk of Disease Recurrence (D-CARE). (2011) (1)
- O5-2 AMEERA-2: Phase 1 study of oral SERD amcenestrant (SAR439859) in Japanese women with ER+/HER2- advanced breast cancer (2022) (1)
- Identifying 31 novel breast cancer susceptibility loci using data from genome-wide association studies conducted in Asian and European women (2019) (1)
- Correction to: The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2018 edition (2021) (1)
- Immune microenvironment in brain metastases of breast cancer. (2017) (1)
- Increased chemosensitivity via BRCA2-independent DNA damage in DSS1- and PCID2-depleted breast carcinomas. (2021) (1)
- Abstract P1-14-01: First report of clinicopathological analysis in neoadjuvant treatment phase in NEOS: A randomized study of adjuvant endocrine therapy with or without chemotherapy for postmenopausal breast cancer patients who responded to neoadjuvant letrozole (2015) (1)
- Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer (2013) (1)
- Effects of ABCB1 and ABCG2 Polymorphisms on the Pharmacokinetics of Abemaciclib Metabolites (M2, M20, M18). (2023) (1)
- A phase Ib study of xentuzumab plus abemaciclib and fulvestrant in patients (pts) with advanced hormone receptor-positive (HR+), HER2-negative breast cancer (BC) with visceral or non-visceral disease. (2021) (1)
- Abstract PS10-35: Early intervention for and management of alpelisib (ALP)-induced hyperglycemia: Case studies from the phase III SOLAR-1 trial (2021) (1)
- Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer. (2023) (1)
- P3-15-01: An Interim Efficacy Analysis of Neoadjuvant Letrozole in the New Primary Endocrine-Therapy Origination Study (NEOS/N-SAS BC06): A Randomized Study of Adjuvant Endocrine Therapy with or without Chemotherapy for Postmenopausal Breast Cancer Patients Who Responded to Neoadjuvant Letrozole. (2011) (1)
- The Absence of Cancer in the Location of a Breast Tissue Marker After Neoadjuvant Chemotherapy may Predict Pathological Complete Response with High Accuracy: Results from a Phase II Trial. (2023) (1)
- Abstract PD5-03: TransNEOS: Validation of the oncotype DX recurrence score (RS) testing core needle biopsy samples from NEOS as predictor of clinical response to neoadjuvant endocrine therapy for postmenopausal estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer patients (2018) (1)
- Abstract OT2-01-04: SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (2017) (1)
- Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib (2021) (1)
- Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial. (2015) (1)
- Phase II study of bevacizumab (Bev) combined with weekly paclitaxel (wPac) as first-line therapy for Japanese patients (pts) with HER2-negative metastatic breast cancer (MBC). (2010) (1)
- Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (2022) (1)
- Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study. (2022) (1)
- Abstract P6-08-21: Low body mass index (BMI) is associated with poor survival in Japanese patients with early breast cancer; an exploratory analysis of prospective randomized phase III trials N-SAS BC02 and 03 (2015) (1)
- Current status of postmastectomy radiation therapy in T1–2 breast cancer with limited positive lymph nodes in Japan: Japan Clinical Oncology Group Survey (2018) (1)
- P321 Analgesia with thoracic wall nerve block for breast reconstruction with expander or implant (2015) (1)
- P1-09-04: A Genetic Predictor for Breast Cancer Risk in a Japanese Population. (2011) (1)
- Bolero-2: A Randomized Phase III Study of Everolimus in Combination with Exemestane: Results of the Japanese Subgroup Analysis (2012) (1)
- Efficacy of neratinib in hormone receptor-positive (HR+) patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer (BC): subgroup analyses from the phase III ExteNET trial (2019) (1)
- Invasion and metastasis of breast cancer matrix - Metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) (1995) (1)
- Impact of germinal center-associated nuclear protein polymorphisms on breast cancer risk and prognosis in a Japanese population (2019) (1)
- Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy (2015) (1)
- Relationship of tumor and stromal autophagy and endocrine responsiveness in breast cancer tissues. (2013) (0)
- Abstract P5-18-01: A randomized clinical trial of postoperative adjuvant therapy for elderly breast cancer patients: Conditions of obtaining informed consent and reasons for declining participation (2016) (0)
- Author reply: Brief screening of breast cancer survivors with distressing fear of recurrence (2016) (0)
- Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial (2021) (0)
- 364PTREATMENT OUTCOMES AND PROGNOSTIC FACTORS FOR PATIENTS WITH BRAIN METASTASES FROM BREAST CANCER: A MULTICENTER COHORT ANALYSIS. (2014) (0)
- Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy (2016) (0)
- SY8-2THE CURRENT STATUS AND FUTURE PERSPECTIVES OF JBCRG IN JAPAN (2014) (0)
- Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2) (2023) (0)
- P130 Investigation by questionnaire of the employment of Japanese breast cancer patients (2015) (0)
- A LONG-TERM SURVIVING CASE OF BREAST CANCER AFTER BRAIN METASTASIS (1996) (0)
- Alpelisib (ALP) + fulvestrant (FUL) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis by presence of visceral metastasis (VM) in the SOLAR-1 trial (2019) (0)
- Abstract GS2-02: GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03 (2023) (0)
- Abstract P4-01-26: Real-world treatment duration of subsequent therapy after palbociclib (PAL) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) in Japan (2023) (0)
- Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130) (2020) (0)
- A phase I/II dose-escalation study of weekly paclitaxel in combination with 5'-deoxy-5-fluorouridine for advanced or recurrent breast cance. (2004) (0)
- 322P Prognostic factors for overall survival (OS) in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC): Analyses from PALOMA-3 (2020) (0)
- A Case of Locally Recurrent Breast Cancer in which Contralateral Lymph Node Metastasis was Diagnosed by Sentinel Lymph Node Biopsy (2013) (0)
- 手術可能な節陽性乳癌におけるドキソルビシンおよびシクロホスファミドに続くタキサン対タキサン単体およびパクリタキセル対ドセタキセルの第III相2×2要因比較―NSASBC02試験の第一回中間解析の結果 (2009) (0)
- A case of pancreatic ascites successfully treated with peritoneal lavage. (1990) (0)
- Abstract P3-14-02: A cohort study to evaluate the efficacy and safety of postoperative adjuvant therapy in HER2-positive elderly breast cancer patients (RESPECT-cohort study) (2020) (0)
- Abstract P3-02-06: Survival impact of early detection of recurrence after surgery in early breast cancer patients (2012) (0)
- Phase I/II pharmacokinetics/pharmacodynamics study of irinotecan and S-1 for recurrent/metastatic breast cancer in patients with select UGT1A1 genotypes (the JBCRG-M01 study) (2016) (0)
- Fine-mapping identifies two additional susceptibility 9q31.2. (2015) (0)
- Abstract PD13-09: Primary analysis from NEOS trial: A randomized phase III study that assessed the long-term prognosis of estrogen receptor positive (ER+) primary breast cancer (PBC) pts who received neoadjuvant endocrine therapy (NET) with/without adjuvant chemotherapy (CT) (2022) (0)
- [Proactive Efforts by Medical Establishments to Support Working Cancer Patients and Formation of Comprehensive Employment Support Networks in Local Communities]. (2019) (0)
- Title Genome-wide association study in east Asians identifies novelsusceptibility loci for breast cancer (2012) (0)
- Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial. (2023) (0)
- The comparison of prognosis between clinical axillary lymph node positive and negative in early breast cancer patients with one or two pathological lymph node metastases (2019) (0)
- The Upfront Therapy for HER2 Positive Breast Cancer Patients (2012) (0)
- Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients (2015) (0)
- Abstract OT2-01-05: A randomized controlled trial comparing post-operative intensive follow-up with standard follow-up in high-risk breast cancer patients (JCOG1204: INSPIRE) (2019) (0)
- Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition (2021) (0)
- Correction to: The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition (2021) (0)
- AOSOP16 DEVELOPMENT OF WEB TOOLS TO PREDICT PATHOLOGICAL RESPONSE TO NEOADJUVANT CHEMOTHERAPY AND AXILLARY LYMPH NODE METASTASIS IN BREAST CANCER PATIENTS (2013) (0)
- A CASE OF PHYLLODES TUMOR IN A JUVENILE WHICH PRESENTED DIFFICULTY IN DIFFERENTIATION FROM GIANT FIBROADENOMA (1997) (0)
- P4-09-25: Impact of Body Mass Index (BMI) for Clinical Outcomes in Japanese Breast Cancer Patients. (2011) (0)
- A CASE OF LATELY RECURRENT BREAST CANCER RECOVERED FROM TRANSVERSAL UPPER THORACIC SPINAL CORD LESION (1992) (0)
- Abstract P4-13-12: Immediate one-stage implant-based breast reconstruction without an acellular dermal matrix in Japanese breast cancer patients (2018) (0)
- P5-11-01: The Accuracy of Preoperative Ultrasonography Guided Vacuum-Assisted Breast Biopsy in Determining Histological Type, ER Status, PgR Status, HER2 Status and Ki67 Level in Invasive Breast Cancer. (2011) (0)
- Abstract P5-02-32: Differential Gene Mutation Landscape in Patients With PIK3CA-altered and Non-altered Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer in the SOLAR-1 Clinical Study (2023) (0)
- P139 Prognostic value of troponin I for chemotherapy-induced cardiac dysfunction in breast cancer patients (2015) (0)
- MO18-1 Impact of cachexia on survival before first-line chemotherapy for metastatic breast cancer (2022) (0)
- Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. (2023) (0)
- Abstract P6-03-05: An Approach for the Differential Diagnosis of Primary Lung Cancer and Breast Cancer Relapse Presenting as a Solitary Pulmonary Nodule in Patients after Breast Surgery (2010) (0)
- SY8-1THE PRESENT AND PERSPECTIVE IN BREAST CANCER STUDY GROUPS OF JCOG (2014) (0)
- Effectiveness of Neo-Adjuvant Systemic Therapy for Basal HER2 type Breast Cancer – Results from Retrospective Cohort Study of Japan Breast Cancer Research Group (JBCRG) – C03 (2018) (0)
- Abstract P2-13-04: Superior efficacy of anastrozole to tamoxifen as adjuvant therapy for postmenopausal patients with hormone-responsive breast cancer. Efficacy results of long-term follow-up data from N-SAS BC 03 trial (2012) (0)
- Abstract P4-21-24: Development of mathematical prediction models to identify disease-free survival events for HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy and trastuzumab (2017) (0)
- Distant disease-free survival (DDFS) discrimination capacity of various pathologic complete response (pCR) definitions according to breast cancer subtypes. (2013) (0)
- Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy. (2023) (0)
- Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy (2023) (0)
- Abstract OT1-07-06: Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease (2020) (0)
- Abstract P3-06-14: DSS1 depletion is a promising strategy increasing chemosensitivity possibly independent of BRCA2 expression (2016) (0)
- The serological assessment of therapeutic effects and relapse by tumor markers in patients with advanced or recurrent breast cancer (1992) (0)
- Microdochectomy experience for patients with nipple discharge from a single institution (2019) (0)
- The prediction of pathological margin using preoperative contrast-enhanced MRI for early breast cancer who performed skin-sparing mastectomy with immediate reconstruction (2017) (0)
- 53O_PREfficacy and safety of palbociclib plus fulvestrant in Asian women with hormone receptor-positive (HR+)/human epidermal growth factor-2 negative (HER2-) metastatic breast cancer (MBC) that progressed on prior endocrine therapy (ET) (2015) (0)
- Reply to T.J.A. Dekker. (2020) (0)
- Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer (2019) (0)
- ASO Author Reflections: The Strengths and Weaknesses of Intraoperative Radiotherapy for Early Breast Cancer and Ipsilateral Tumor Recurrence (2019) (0)
- Abstract P2-01-18: Preoperative axillary imaging with ultrasonography: Among the breast cancer patients with lymph node metastases, can we identify the patients who may omit axillary dissection? (2015) (0)
- Abstract P3-06-16: The difference of molecular subtypes and prognosis after surgery for breast cancer patients with each blood types (2013) (0)
- 5MO Evaluation of pathological complete response (pCR) after neoadjuvant chemo-radiation therapy for primary breast cancer (JCOG0306A1) (2020) (0)
- IMpassion130: Efficacy in immune biomarker subgroups of atezolizumab plus nab-paclitaxel in patients with triple-negative BC (2019) (0)
- Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial. (2022) (0)
- Abstract P6-16-08: Prognostic factor of HER2-positive breast cancer patients developed brain metastasis: A multicenter retrospective analysis (2015) (0)
- Abstract OT1-18-01: A randomized controlled phase III study of bevacizumab and paclitaxel in combination with atezolizumab as a treatment for patients with locally advanced or metastatic hormone receptor-positive HER2 negative breast cancer: JCOG1919E/AMBITION study (2022) (0)
- Abstract P3-16-04: Estimation of willingness-to-pay for breast cancer treatments through contingent valuation method in Japanese breast cancer patients (JCOG1709A): The main study findings (2022) (0)
- Association between bevacizumab with cancer drug therapies and drug-induced interstitial lung disease in patients with solid tumor: A systematic review and meta-analysis of randomized clinical trials. (2022) (0)
- Estimation of absolute benefit of S-1 postoperative therapy for ER-positive, HER2-negative breast cancer: Exploratory analysis of the phase III potent trial. (2020) (0)
- [Axillary lymph node dissection in clinically node-positive breast cancer]. (2002) (0)
- P17-8 Clinical impact of next-generation sequencing in patients with breast cancer: A single institute study (2021) (0)
- Abstract OT3-01-01: A single-arm confirmatory study to evaluate the efficacy of non-surgical therapy for HER2 positive early breast cancer with clinical complete response after primary systemic therapy: (JCOG1806) (2023) (0)
- Assessment of uterus, bone, serum lipids, and hormones in postmenopausal breast cancer patients treated with TAS-108, a novel steroidal antiestrogen: Results of a randomized phase II study. (2009) (0)
- Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines, 2018 edition: the tool for shared decision making between doctor and patient (2021) (0)
- Contents Vol. 72, 2007 (2008) (0)
- Abstract 3654: Associations of body mass index and its change with breast cancer risk by molecular subtypes: a case-control study in Japanese women. (2013) (0)
- Patient-reported assessment and objective assessment of edema among breast cancer patients receiving docetaxel plus cyclophosphamide (TC) (2017) (0)
- Abstract 2913: Entinostat (KHK2375), class I histone deacetylase inhibitor, regulates human Treg function by decreasing Foxp3 expression and effector Treg population (2020) (0)
- The significance of biopsy scar excision at the time of skin- or nipple-sparing mastectomy with immediate breast reconstruction (2021) (0)
- Abstract P6-07-16: Evaluation of circulating tumor cell as a marker of prognosis and efficacy in a randomized phase III study in HER2 negative metastatic breast cancer patients treated with capecitabine and docetaxel: JO21095 study (2012) (0)
- Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis, 2018 Edition (2021) (0)
- ISS3-2-4Predictions of pathological response after preoperative chemotherapy plus trastuzumab in HER2-positive breast cancer (2015) (0)
- Abstract 820: Molecular epidemiological studies of germinal center-associated nuclear protein (ganp) in the development of human sporadic breast cancers (2016) (0)
- Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial (2022) (0)
- Lack of impact of the ALDH2 rs671 variant on breast cancer development in Japanese BRCA1/2‐mutation carriers (2022) (0)
- Abstract P1-12-08: Biomarker analysis of hepatotoxicity in a Phase II study of nivolumab, abemaciclib and endocrine therapy in patients with HR-positive, HER2-negative breast cancer: WJOG11418BTR NEWFLAME_TR (2023) (0)
- A CASE OF PHYLLODES TUMOR OF THE RIGHT BREAST TREATED WITH AN EMERGENCY OPERATION (1997) (0)
- A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncollgy Group Study (JCOG1607, HERB TEA study). (2021) (0)
- Abstract P6-01-04: Changes in Ki67 expression in breast cancer during the menstrual cycle and menopause (2015) (0)
- Abstract P2-15-01: A randomized, multicenter, phase II study evaluating the efficacy of interventional maintenance endocrine therapy with bevacizumab following fixed cycles of bevacizumab plus paclitaxel in advanced/metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 BOOSTER trial (2020) (0)
- Abstract P5-09-07: Impact of germinalcenter-associated nuclear protein polymorphisms on breast cancer risk and prognosis in a Japanese population (2017) (0)
- Satisfaction survey on a preoperative explanation method using three-dimensional breast imaging for breast cancer patients considering breast-conserving surgery (2022) (0)
- Abstract CT165: An open label, multi-cohort, phase Ib study of xentuzumab and abemaciclib: Preliminary results from the advanced non-small cell lung cancer (NSCLC) cohort (2020) (0)
- Corrigendum to: A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study). (2021) (0)
- Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2:HER2 dimerization in a clinic-based cohort of patients with metastatic breast cancer (2007) (0)
- Abstract P2-01-09: Circulating tumor cells (CTCs) in the venous drainage of the breast in patients with primary breast cancer (2018) (0)
- CHANGES OF SERUM c-erbB-2 PROTEIN VALUES IN PATIENTS WITH RECURRENT BREAST CANCER (1993) (0)
- Trial in progress: A phase 1, multicenter, open-label, dose-exploration and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG650 in subjects with advanced solid tumors. (2021) (0)
- A CASE OF GIANT LIPOMA OF THE BREAST (1997) (0)
- Abstract P2-12-13: Withdrawn (2018) (0)
- MO11-7 The decision of adjuvant treatment using OncotypeDX and outcome in early breast cancer patients (2021) (0)
- Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer (2021) (0)
- Impact of BMI on survival and toxicity in early breast cancer: An exploratory analysis of prospective randomized phase III study N-SAS BC02 and 03. (2015) (0)
- Abstract OT2-11-08: AMEERA-5 : A randomized, double-blind phase 3 study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer (2022) (0)
- PO67 CLINICAL BENEFIT OF ETHINYLESTRADIOL AS A SALVAGE ENDOCRINE THERAPY FOR THE HEAVILY PRETREATED METASTATIC BREAST CANCER (2013) (0)
- PSY6-1 The future perspective of Asian collaboration based on experience of investigator initiated global clinical trials (PENELOPE-B and PALLAS) (2021) (0)
- 415 Comparison of two Phase II trials evaluating three dosing regimens of fulvestrant in Japanese vs non-Japanese postmenopausal women with advanced breast cancer (FINDER1 and FINDER2) (2010) (0)
- Subject Index Vol. 72, 2007 (2008) (0)
- Title Evaluating the 21-gene assay Recurrence Score ® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer (2018) (0)
- [Effectiveness of breast ultrasound]. (2007) (0)
- Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis (2020) (0)
- Abstract P6-06-20: Predictive factors for pathologic complete response and disease-free survival after neoadjuvant chemotherapy with trastuzumab: A multicenter retrospective observational study in patients with HER2-positive primary breast cancer (JBCRG-C03 study) (2013) (0)
- Abstract P5-09-01: Neoadjuvant hormonal therapy plus palbociclib versus hormonal therapy plus placebo in women with operable, hormone sensitive and HER2-negative primary breast cancer (2023) (0)
- PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup (2022) (0)
- Abstract OT3-4-01: A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (JCOG1017 study; PRIM-BC) (2015) (0)
- A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients (2019) (0)
- Management of breast cancer in older patients. (2022) (0)
- Title Clinical significance of the expression of autophagy-associated marker , beclin 1 , in breast cancer patients who (2019) (0)
- PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy. (2016) (0)
- O1–027A PHASE IB TRIAL OF RAMUCIRUMAB (RAM), IN COMBINATION WITH DOCETAXEL (D) IN JAPANESE PATIENTS WITH ADVANCED METASTATIC BREAST CANCER (MBC) (2013) (0)
- Analysis of biomarkers (P PTEN, and IGF-IR) after preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER2-overexpressing breast cancer (Tokai Breast Cancer Clinical Research Group: TBCRG) (2008) (0)
- Abstract PS9-57: Estimation of willingness-to-pay for breast cancer treatments through contingent valuation method in Japanese breast cancer patients (JCOG1709A); preliminary study findings (2021) (0)
- A Case of Breast Metastasis from Rectal Cancer (2016) (0)
- Lack of concordance between Ki67 labeling index and 21-gene Breast Recurrence Score® test results in patients with ER+, HER2−, clinically node-negative breast cancer: a secondary analysis of TransNEOS neoadjuvant study (2019) (0)
- Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma (2016) (0)
- [Anti-angiogenic therapy for breast cancer--problems and future directions]. (2012) (0)
- 20th International Symposium on Glycoconjugates Glycans: From Molecules to Structures to Therapeutics November 29–December 4, 2009 Caribe Hilton Hotel, San Juan, Puerto Rico. USA www.glyco20.org (2009) (0)
- 137TiP A phase III study of alpelisib and fulvestrant for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1) (2016) (0)
- A PLAIN-LANGUAGE SUMMARY OF THE SOLAR-1 TRIAL: STUDYING ALPELISIB WITH FULVESTRANT IN PATIENTS WITH HR+, HER2– ADVANCED BREAST CANCER WHO HAD PREVIOUSLY RECEIVED AN AROMATASE INHIBITOR (2019) (0)
- Abstract P4-11-02: Endocrine-related symptoms during neoadjuvant endocrine therapy for breast cancer: Agreement between patient and physician reporting in a prospective clinical trial (2016) (0)
- Abstract P3-11-05: A phase Ib multi-cohort study of xentuzumab and abemaciclib in patients (pts) with solid tumors and breast cancer (BC) - Initial report of four dose-finding cohorts (2020) (0)
- Abstract P5-14-02: Postmastectomy radiation improves loco-regional control for patients with advanced breast cancer treated with neoadjuvant chemotherapy (2013) (0)
- A single-arm confirmatory study to evaluate the efficacy of nonsurgical therapy for HER2-positive early breast cancer with clinical complete response after primary systemic therapy (JCOG1806: AMATERAS-BC study). (2021) (0)
- Association of p53 codon 72 polymorphism with resistance to adjuvant therapy in primary breast cancer (2007) (0)
- P1-06-21: Relationship between Body Mass Index and Preoperative Treatment Response to Aromatase Inhibitor Exemestane in Postmenopausal Patients with Primary Breast Cancer. (2011) (0)
- Efficacy of Trastuzumab Containing Retreatment after Progression on Lapatinib Therapy in Japanese Patients with HER2-Positive Metastatic Breast Cancer (2012) (0)
- ALTERNATIVE (EGF114299): A study of lapatinib, trastuzumab, and endocrine therapy in patients who received neo-/adjuvant trastuzumab (IV) and endocrine therapy. (2012) (0)
- Abstract PD14-05: Genomic profiling and clinical outcomes with first-line atezolizumab andnab-paclitaxel in triple-negative breast cancer: An exploratory analysis from the phase 3 IMpassion130 trial (2021) (0)
- Clinical Trial Note Application of a Continual Reassessment Method to a Phase I Clinical Trial of Capecitabine in Combination with Cyclophosphamide and Epirubicin (CEX) for Inoperable or Recurrent Breast Cancer (2004) (0)
- Abstract P1-16-07: Pharmacogenomics-pharmacokinetics study of selective estrogen-receptor modulators with intra-patient dose-escalation for Japanese breast cancer patients (2016) (0)
- Differences in baseline risk estimated by physicians and patients with early breast cancer. (2021) (0)
- Detection of presumed germline pathogenic variants of hereditary breast cancer predisposition genes in circulating tumor DNA: SCRUM-Japan MONSTAR-SCREEN. (2022) (0)
- A phase II, randomized, open-label, dose-finding study of TAS-108, a novel steroidal antiestrogen, administered orally in postmenopausal women with advanced or metastatic breast cancer. (2009) (0)
- 93OPhase 2 study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC): Japanese subgroup results of KEYNOTE 086 (2017) (0)
- Abstract P1-01-05: Adjuvant S-1 plus endocrine therapy for estrogen receptor-positive, HER2-negative, primary breast cancer: updated overall survival analysis from the POTENT trial (2023) (0)
- Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study (2017) (0)
- A LONG-TERM SURVIVING CASE OF ADVANCED BREAST CANCER WITH LYMPHANGITIS TYPE LUNG METASTASIS (1992) (0)
- Abstract PD3-12: PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial (2018) (0)
- Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition. (2023) (0)
- P295 Comparison of complication, cosmetic outcome with or without irradiation after breast reconstruction (2015) (0)
- Abstract P6-11-21: Oncology care providers’ attitudes, practices, barriers and facilitators of physical activity promotion in breast cancer survivors: A nation-wide cross sectional web-based survey (2020) (0)
- ASO Visual Abstract: The Absence of Cancer in the Location of a Breast Tissue Marker After Neoadjuvant Chemotherapy May Predict Pathological Complete Response with High Accuracy-Results from a Phase II Trial. (2023) (0)
- Correction to: Histological classification of breast tumors in the General Rules for Clinical and Pathological Recording of Breast Cancer (18th edition) (2020) (0)
- Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355. (2023) (0)
- AOSOP14 MATRIX-PRODUCING CARCINOMA OF THE BREAST: IMMUNOHISTOCHEMICAL EXPRESSION PROFILES OF A RARE SUBTYPE OF BREAST CARCINOMA (2013) (0)
- 292PProspective observational study of peripheral neuropathy in breast cancer patients treated with eribulin (2017) (0)
- Abstract P2-18-03: Feasibility of sentinel node biopsy following neoadjuvant chemotherapy in cytology-proven node positive breast cancer before chemotherapy (2013) (0)
- PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial (2019) (0)
- Survey on QOL and cosmesis after intraoperative radiotherapy (IORT) in a multicenter phase II study of patients with early breast cancer (2017) (0)
- Contents Vol. 85, 2013 (2013) (0)
- PS2-2 KEYNOTE-355 Asian subset: Pembrolizumab + chemotherapy vs placebo + chemotherapy for triple-negative breast cancer (2022) (0)
- Neoadjuvant docetaxel (DOC 75) followed by fluorouracil, epirubicin, cyclophosphamide (FEC 100) in primary operable breast cancer: results of a multicenter phase II trial (2008) (0)
- 349PRISK OF LOCOREGIONAL RECURRENCE AFTER MASTECTOMY BY HORMONE RECEPTOR STATUS AND HER2 STATUS IN BREAST CANCER PATIENTS WITH 1-3 POSITIVE NODES. (2014) (0)
- Studies on Agreement Rates for Determining Mammographic Parenchymal Pattern/Density (2001) (0)
- Abstract P3-12-06: Clinicopathological Analysis of Breast Cancer Patients with Brain Metastases: (2012) (0)
- THE INFLUENCE OF ANESTHESIA METHOD ON CREATINE PHOSPHOKINASE (CPK) AFTER APPENDECTOMY (1991) (0)
- Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study (2022) (0)
- ISY3-3The perspective of anti-HER2 therapy for HER2 positive breast cancer (2015) (0)
- Preoperative endocrine therapy as a predictive biomarker of adjuvant chemotherapy. (2017) (0)
- Arthralgia induced by endocrine therapy with or without cyclin-dependent kinase 4/6 inhibitors in breast cancer: A systematic review and meta-analysis. (2022) (0)
- Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial (2021) (0)
- A CASE OF CARCINOMA IN PLEOMORPHIC ADENOMA IN THE SUBMANDIBULAR GLAND WITH CARDIAC METASTASIS (1998) (0)
- [Treatment Strategy in Patients with Oligometastatic Breast Cancer]. (2017) (0)
- P1-16-01: A Randomized, Double-Blinded, Controlled Study of Exemestane vs. Anastrozole for the First-Line Treatment of Postmenopausal Japanese Women with Hormone Receptor Positive Advanced Breast Cancer. (2011) (0)
- IS2. Breast Cancer (2012) (0)
- Atezolizumab + nab-paclitaxel as first line therapy in Japanese patients with TNBC: A subgroup analysis of IMpassion130 (2019) (0)
- Abstract P5-14-25: A double-blind phase 2 trial of preventative use of surgical gloves for paclitaxel-induced peripheral neuropathy (2020) (0)
- BOLERO-2: Everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone receptor-positive breast cancer. (2012) (0)
- Adjuvant Trastuzumab Without Chemotherapy For Treating Early HER2-Positive Breast Cancer In Older Patients: A Cohort Study Accompanying With The RESPECT Trial (2021) (0)
- Alpelisib (ALP)+fulvestrant (FUL) in patients from Japan with advanced breast cancer: Subgroup analysis of SOLAR-1 trial (2019) (0)
- Abstract P3-11-06: A phase 1 study of KHK2375 (entinostat) as monotherapy and in combination with exemestane in Japanese patients with hormone receptor-positive, HER2-negative, advanced or recurrent breast cancer (2018) (0)
- Abstract P6-09-12: A functional single nucleotide polymorphisms in ABCC11, rs17822931, is associated with the risk of breast cancer in Japanese (2018) (0)
- Analysis of health-related quality of life during neoadjuvant endocrine therapy with letrozole in postmenopausal breast cancer patients: N-SAS BC06 trial. (2013) (0)
- P104 Patterns of recurrence and survival in HER2+ patients relapsing after receiving adjuvant trastuzumab (2015) (0)
- Abstract CT517: Amcenestrant, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/HER2- advanced breast cancer (aBC): combined biomarker analyses from a Phase 1/2 study in postmenopausal women and a Phase 1 study in postmenopausal Japanese women (2022) (0)
- Abstract P5-13-12: Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/ hepatitis B core antibody positive and/or hepatitis B surface antibody positive breast cancer patients who receive chemotherapy (2013) (0)
- [Results of survey conducted on perioperative chemotherapy and supportive care in primary breast cancer (JBCRG01)]. (2007) (0)
- P289 Retrospective study of pregnancy outcome after breast cancer (2023) (0)
- Is ypT0/isn0 acceptable for Japanese population? JBCRG’s perception. (2013) (0)
- Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis. (2023) (0)
- Abstract 1112: Forced reduction of DSS1, a member of TREX2 complex, highly sensitizes chemotherapy to breast cancer cells in a BRCA2-independent manner (2017) (0)
- Abstract P4-11-09: A randomized controlled trial of postoperative adjuvant therapy for elderly breast cancer patients: Comparison of health-related quality of life between clinical trial participants and decliners (2016) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Hiroji Iwata?
Hiroji Iwata is affiliated with the following schools:
- University of Calgary
- Medical University of Vienna
- University of Sheffield
- Chubu University
- University of Tokyo
- Fukushima Medical University
- Showa University
- Kumamoto University
- National Taiwan University
- Kyoto University
- Seoul National University
- Padjadjaran University
- Nagoya University
- Institute of Science Tokyo
- Queen Mary University of London
- Okayama University
- Kindai University
